Acute kidney injury (AKI) affects 10–15% of all hospitalized patients and 30–50% of ICU patients — significantly increasing 30-day mortality (4–6× in severe AKI), hospital length of stay, and conversion to chronic kidney disease. Yet many hospital-acquired AKI events are preventable through proactive nephrotoxin avoidance, volume optimization, and hemodynamic management — making AKI prevention a quality metric in modern inpatient care.
KDIGO Staging and Recognition
KDIGO AKI criteria: any of the following within 48 hours: serum creatinine increase ≥0.3mg/dL, or 1.5× baseline creatinine within 7 days, or urine output <0.5mL/kg/h for >6 hours. KDIGO stages: Stage 1 — creatinine 1.5–1.9× baseline or ≥0.3mg/dL rise, or UO <0.5mL/kg/h for 6–12h. Stage 2 — creatinine 2.0–2.9× baseline, or UO <0.5mL/kg/h >12h. Stage 3 — creatinine ≥3× baseline or ≥4.0mg/dL, or UO <0.3mL/kg/h >24h, or anuria ≥12h, or new RRT. Recognition challenge: serum creatinine lags AKI by 24–48 hours — novel biomarkers (NGAL, KIM-1, TIMP-2×IGFBP7) detect AKI 12–24 hours earlier but are not universally available. Urine output monitoring in ICU patients provides real-time AKI signal.
Prevention: Nephrotoxins and Volume
NSAIDs: block prostaglandin-mediated afferent arteriolar dilation — significantly impair renal perfusion in volume-depleted or hemodynamically compromised patients. Avoid in hospitalized patients with any cardiovascular or volume instability. ACE inhibitors/ARBs: reduce glomerular efferent arteriolar tone — generally hold in acute illness when volume status is uncertain. Aminoglycosides: direct tubular toxicity — use once-daily dosing (extended-interval), monitor trough levels, limit course duration, and use alternatives when available. Contrast-associated AKI (CA-AKI): the "contrast nephropathy" epidemic was substantially overstated — recent evidence shows modern iso-osmolar or low-osmolar iodinated contrast in appropriately hydrated patients causes CA-AKI far less frequently than historical estimates. IV saline hydration (1–1.5mL/kg/h for 6h pre and 6h post) remains standard pre-procedure prophylaxis for patients with eGFR 30–60. IV sodium bicarbonate and N-acetylcysteine: meta-analyses show no clear benefit over saline hydration alone — NAC is low-cost/low-risk and still often used. Vancomycin: combination vancomycin + piperacillin-tazobactam substantially increases AKI risk versus vancomycin + cefepime — multiple meta-analyses. Prefer cefepime or meropenem as the beta-lactam partner when vancomycin is required. For hospital pharmacy and infusion departments, our IV vascular access supplies and laboratory supplies support medication monitoring and fluid management in AKI prevention protocols.
